Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
about
Minor HIV-1 variants with the K103N resistance mutation during intermittent efavirenz-containing antiretroviral therapy and virological failureA mixture of hierarchical joint models for longitudinal data with heterogeneity, non-normality, missingness, and covariate measurement error.Bayesian inference on mixed-effects varying-coefficient joint models with skew- t distribution for longitudinal data with multiple features.Combining cross-sectional and prospective data methods to improve transition parameter estimation for characterizing the accumulation of HIV-1 drug resistance mutations.Bayesian quantile regression for nonlinear mixed-effects joint models for longitudinal data in the presence of mismeasured covariate errors.Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis.Buckley-James boosting for survival analysis with high-dimensional biomarker data.Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.Joint modeling of longitudinal data and informative dropout time in the presence of multiple changepoints.Amprenavir and efavirenz pharmacokinetics before and after the addition of nelfinavir, indinavir, ritonavir, or saquinavir in seronegative individualsA Semiparametric Bayesian Approach to Multivariate Longitudinal Data.Sensitive phenotypic detection of minor drug-resistant human immunodeficiency virus type 1 reverse transcriptase variants.Clinical, virological and immunological responses in Danish HIV patients receiving raltegravir as part of a salvage regimen.Outcomes of patients on dual-boosted PI regimens: experience of the Swiss HIV cohort studyPopulation pharmacokinetics and pharmacodynamics of efavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398.Pharmacokinetics of an indinavir-ritonavir-fosamprenavir regimen in patients with human immunodeficiency virusDose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavirPharmacokinetic interaction between efavirenz and dual protease inhibitors in healthy volunteers.Bayesian analysis of nonlinear mixed-effects mixture models for longitudinal data with heterogeneity and skewness.Antiretroviral therapy for adults infected with HIV: Guidelines for health care professionals from the Quebec HIV care committeeBarriers to antiretroviral therapy adherence and plasma HIV RNA suppression among AIDS clinical trials group study participantsA moving blocks empirical likelihood method for longitudinal data.Lower CD4 cell count and higher virus load, but not antiretroviral drug resistance, are associated with AIDS-defining events and mortality: an ACTG Longitudinal Linked Randomized Trials (ALLRT) analysis.Effect of natural polymorphisms in the HIV-1 CRF02_AG protease on protease inhibitor hypersusceptibilityTipranavir: a protease inhibitor for multi-drug resistant HIV-1.Antiretroviral treatment regimen outcomes among HIV-infected prisoners.Fosamprenavir calcium plus ritonavir for HIV infection.Persistence of virological benefits following directly administered antiretroviral therapy among drug users: results from a randomized controlled trialAIDS clinical trials group longitudinal linked randomized trials (ALLRT): rationale, design, and baseline characteristicsFlexible regression model selection for survival probabilities: with application to AIDS.Peripheral neuropathy in ART-experienced patients: prevalence and risk factorsRegulatory T cells and the risk of CMV end-organ disease in patients with AIDS.Estimating mono- and bi-phasic regression parameters using a mixture piecewise linear Bayesian hierarchical model.Bayesian Experimental Design for Long-Term Longitudinal HIV Dynamic Studies.Cost-Effectiveness of Antiretroviral Therapy for Multidrug-Resistant HIV: Past, Present, and Future.Virologic efficacy of boosted double versus boosted single protease inhibitor therapy.Skew-t partially linear mixed-effects models for AIDS clinical studies.Likelihood-based inferences about the mean area under a longitudinal curve in the presence of observations subject to limits of detection.A DYNAMIC BAYESIAN NONLINEAR MIXED-EFFECTS MODEL OF HIV RESPONSE INCORPORATING MEDICATION ADHERENCE, DRUG RESISTANCE AND COVARIATES().
P2860
Q28478779-A6CCCA9A-67A6-4968-9561-980C8EEA9E01Q30886478-01EDF1E4-41DB-4A94-BF9B-7BDF5F3B1C20Q30891275-44A6A23C-714B-48C1-BABE-C2CC774CDCB3Q31107886-DB98AC3B-02F8-48DE-982A-5A202E75091CQ31147974-C8EA7326-9640-4602-BCC4-E6EF52D8316FQ33592278-79FC5DA8-79AB-4EC4-AE39-8810F3C1D84DQ33624066-EB861AA1-3643-4445-AFFB-AB6884884983Q33649563-576FBD3E-FB68-4641-ADC4-BA75672B1DB6Q33714377-DC24513B-A495-4909-8D31-F86C6384FFFDQ33825415-A4081CCB-9EF9-43B0-9F85-B9ACD9C7F94FQ33938221-F2429BF2-AD94-4C57-B334-5F50E0F2D3FFQ33951888-8C93CEE1-7B6A-4513-96C4-74560C70F822Q34143613-B3BA7C3F-7A04-4293-857B-4C7E1C2EA65EQ34144189-68F88424-02F0-4641-A35B-B202B20C8AECQ34292138-5E35F85C-BA9D-45DB-A2CA-D2FD9176D90AQ34721793-3C639FAB-D345-4D6F-940A-3C08C3C3D036Q34776424-43711B8D-FB24-4F4A-BBCC-9158EEB63CF7Q34973838-439E3CAD-309C-41A0-B441-34D5EB75A277Q35018246-50040D38-9E83-4E3B-A959-E4453ECFC046Q35119307-ABE9A59A-B211-4AED-8FE2-3BD37AE8315AQ35124959-BA49BE97-7653-4BB0-8F71-E4084F6ABEECQ35156644-C7D7A490-56DB-4404-8DFD-83873FA8E45FQ35628616-8D6669B9-F26F-45EB-96EA-DF874C008872Q35872395-F788BF34-BD0B-4928-BDA5-BEB8C7F9B382Q35941273-2D95BC35-1A92-4ABD-B3E5-0E950E4AD81BQ36349653-D564C6EE-EA8A-495A-A14F-15CB7099F52EQ36692794-793637BA-4729-4EBD-8DF4-F2F4760B6F1DQ36839698-8711567D-3997-42B0-999F-FA9EFF8BB6D4Q37163341-A56153F4-A1A5-403C-B0B9-1D8147C705B7Q37246041-4482CBD7-FE2E-4AD2-9D1A-6C34C80C29CAQ37479954-809DCC87-CF95-400A-8E0E-43540E17D133Q37662415-CC7B4974-4FE2-459A-AB90-DC01628577EDQ37695072-A4267537-8682-4A6A-A142-30A9F3EB4827Q38671908-28AB546A-F753-4373-B9D6-4F58E142604BQ39435588-362EE92A-EE02-46FD-90D5-250A172595D1Q39511996-B6D4C729-683E-4731-85EF-A10A2B5A77F9Q39640281-B12BC0C5-A045-4E9E-979B-348769556BDAQ40228684-9255FC01-4EE4-45BB-8823-3109EECB916CQ41127274-56C51B42-0561-4F64-A9A5-91ED6DA5142EQ41153820-0DE6763D-3864-4CE4-9A44-189F2EA46000
P2860
Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
Dual vs single protease inhibi ...... t failure: a randomized trial.
@en
Dual vs single protease inhibi ...... t failure: a randomized trial.
@nl
type
label
Dual vs single protease inhibi ...... t failure: a randomized trial.
@en
Dual vs single protease inhibi ...... t failure: a randomized trial.
@nl
prefLabel
Dual vs single protease inhibi ...... t failure: a randomized trial.
@en
Dual vs single protease inhibi ...... t failure: a randomized trial.
@nl
P2093
P356
P1476
Dual vs single protease inhibi ...... t failure: a randomized trial.
@en
P2093
AIDS Clinical Trials Group 398 Study Team
Alfred J Saah
Carol Brosgart
Cheryl N Karol
Florin Vaida
John W Mellors
Judith A Aberg
Kara K Bennett
Laura J Bessen
Lawrence Joseph Wheat
P304
P356
10.1001/JAMA.288.2.169
P407
P577
2002-07-01T00:00:00Z